EX-10.1 2 d340942dex101.htm LICENSE AND CO-DEVELOPMENT AGREEMENT LICENSE AND CO-DEVELOPMENT AGREEMENT BETWEEN THRESHOLD PHARMACEUTICALS AND MERCK KGAA LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • May 5th, 2020 • London
THIS LICENSE AND CO-DEVELOPMENT AGREEMENT (the “Agreement”) is made and entered into by and between MERCK KGaA, a corporation organized and existing under the laws of Germany and having a principal place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany (hereinafter referred to as “Merck” or “Licensee”), and THRESHOLD PHARMACEUTICALS, a corporation organized and existing under the laws of California and having its principal office at 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA (hereinafter referred to as “Threshold” or “Licensor”). Merck and Threshold may each be referred to herein individually as a “Party” and collectively as the “Parties.”
LICENSE AND CO-DEVELOPMENT AGREEMENT BY AND BETWEEN GENZYME CORPORATION AND ISIS PHARMACEUTICALS, INC. June 24, 2008License and Co-Development Agreement • August 11th, 2008 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Co-Development Agreement (together with all Exhibits, Schedules and other attachments hereto, this “Agreement”), is dated as of the 24th day of June, 2008 (the “Execution Date”), by and between Genzyme Corporation, a Massachusetts corporation (“Genzyme”) and Isis Pharmaceuticals, Inc., a Delaware corporation (“Isis”). Genzyme and Isis each may be referred to herein individually as a “Party” or collectively as the “Parties.”
THE SYMBOL “[***]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED LICENSE AND CO-DEVELOPMENT...License and Co-Development Agreement • September 9th, 2019 • BioNTech SE • Biological products, (no disgnostic substances)
The following activities will be subject to a detailed 2-way transfer plan for know-how and materials between BioNTech and Genevant on an as-needed basis to support the collaboration:
License and Co-Development Agreement By and Between Cell Therapeutics, Inc., Cell Therapeutics Europe S.r.l. and Novartis International Pharmaceutical Ltd.License and Co-Development Agreement • September 18th, 2006 • Cell Therapeutics Inc • Pharmaceutical preparations • New York
This AGREEMENT is made as of the 15th day of September, 2006 (the “Execution Date”), by and between Novartis International Pharmaceutical Ltd., a limited company organized and existing under the laws of Bermuda (“Novartis”); Cell Therapeutics, Inc., a corporation organized and existing under the laws of the State of Washington (“CTI”); and Cell Therapeutics Europe S.r.l., a corporation organized and existing under the laws of Italy (“CTI Europe” and, together with CTI, “Licensor”). Novartis and Licensor are each referred to individually as a “Party” and together as the “Parties.”
AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • March 6th, 2014 • Threshold Pharmaceuticals Inc • Pharmaceutical preparations
THIS AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENT (the “Amendment”) is made and entered into by and between MERCK KGaA, a corporation organized and existing under the laws of Germany and having a principal place of business at Frankfurter Strasse 250, 64293 Darmstadt, Germany (hereinafter referred to as “Merck” or “Licensee”), and THRESHOLD PHARMACEUTICALS, a corporation organized and existing under the laws of California and having its principal office at 170 Harbor Way, Suite 300, South San Francisco, CA 94080, USA (hereinafter referred to as “Threshold” or “Licensor”), effective December 2, 2013. Merck and Threshold may each be referred to herein individually as a “Party” and collectively as the “Parties.”
Confidential Materials omitted & filed separately with the SEC. Double asterisks denote omissions. SECOND AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • April 15th, 2016 • Aptevo Therapeutics Inc.
THIS SECOND AMENDMENT (“Second Amendment”) effective as of December 7 2015 (“Effective Date”), is made by and between MorphoSys AG, a German corporation (registered at the District Court of Munich, HRB121023) having an office and place of business at Lena-Christ-Str. 48, 82152 Martinsried/Planegg, Germany, (collectively with its affiliates, “MorphoSys”) and Emergent Product Development Seattle, LLC, a US corporation (registered in Delaware, N° 4858233) having an office and place of business at 2401 Fourth Avenue, Suite 1050, Seattle, Washington, USA (“Emergent”).
LICENSE AND CO-DEVELOPMENT AGREEMENT by and among WYETH, acting through its WYETH PHARMACEUTICALS DIVISION, WYETH-WHITEHALL PHARMACEUTICALS, INC., WYETH- AYERST LEDERLE, INC., and PROGENICS PHARMACEUTICALS, INC. and PROGENICS PHARMACEUTICALS NEVADA,...License and Co-Development Agreement • March 15th, 2006 • Progenics Pharmaceuticals Inc • Pharmaceutical preparations • New York
This License and Co-Development Agreement (the “Agreement”) is entered into this 23rd day of December, 2005 (the “Effective Date”), by and among Wyeth, acting through its Wyeth Pharmaceuticals Division, a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 500 Arcola Road, Collegeville, Pennsylvania 19426, Wyeth-Whitehall Pharmaceuticals, Inc., a corporation having a principal place of business at Road No. 3, Kilometer 142.1, Guayama, Puerto Rico 00784, and Wyeth-Ayerst Lederle, Inc. a corporation having a principal place of business at 65th Infantry Road, Kilometer 9.7, Carolina, Puerto Rico 00987-4904 (collectively “Wyeth”) and Progenics Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware and having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, NY 10591 (“Progenics”) and Progenics Pharmaceuticals Nevada, Inc., a corporation organized and existi
THIRD AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • December 15th, 2016 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
THIS THIRD AMENDMENT (“Third Amendment”) effective as of December 8, 2016 (“Effective Date”), is made by and between MorphoSys AG, a German corporation (registered at the District Court of Munich, HRB121023) having an office and place of business at Lena-Christ-Str. 48, 82152 Martinsried/Planegg, Germany, (collectively with its affiliates, “Morphosys”) and Aptevo Research and Development LLC (previously Emergent Product Development Seattle, LLC), a US corporation (registered in Delaware, N° 4858233) having an office and place of business at 2401 Fourth Avenue, Suite 1050, Seattle, Washington, USA (“Aptevo”).
REDACTED PORTIONS OF THIS EXHIBIT ARE MARKED BY AN***. Agreement between Shenyang Sunshine Pharmaceutical Company and Epitomics, Inc. License and Co- development of anti-TNFalpha monoclonal antibody therapeuticsLicense and Co-Development Agreement • January 19th, 2007 • 3SBio Inc. • California
This term sheet is between Shenyang Sunshine Pharmaceutical Co. Ltd (Sunshine) and Epitomics Inc. (Epitomics). This document is to describe a developing and anticipated ongoing formal Licensing and Co-development relationship between the two companies in the field of commercializing anti-TNFalpha monoclonal antibodies to be used as therapeutic agents.
AMENDMENT NO 1 TO THE LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • August 7th, 2008 • Emergent BioSolutions Inc. • Pharmaceutical preparations • Delaware
Sanofi Pasteur S.A., a company organized and existing under the laws of the Republic of France, registered under the number 349 505 370 – Lyon (France), having its registered office at 2 avenue Pont Pasteur, 69007 LYON, France.
ContractLicense and Co-Development Agreement • October 16th, 2015 • Basilea Pharmaceutica Ltd. • Pharmaceutical preparations
[***] INDICATES MATERIAL THAT HAS BEEN OMITTED AND FOR WHICH CONFIDENTIAL TREATMENT HAS BEEN REQUESTED. ALL SUCH OMITTED MATERIAL HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO 17 C.F.R. SECTIONS 200.80(B)(4) AND 240.24B-2.
ContractLicense and Co-Development Agreement • September 25th, 2019
Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
FOURTH AMENDMENT TO LICENSE AND CO-DEVELOPMENT AGREEMENTLicense and Co-Development Agreement • August 10th, 2017 • Aptevo Therapeutics Inc. • Pharmaceutical preparations
THIS FOURTH AMENDMENT (“Fourth Amendment”) effective as of June 19, 2017 (“Effective Date”), is made by and between MorphoSys AG, a German corporation (registered at the District Court of Munich, HRB121023) having an office and place of business at Semmelweisstrasse 7, 82152Planegg, Germany, (collectively with its affiliates, “Morphosys”) and Aptevo Research and Development LLC (previously Emergent Product Development Seattle, LLC), a US corporation (registered in Delaware, N° 4858233) having an office and place of business at 2401 Fourth Avenue, Suite 1050, Seattle, Washington, USA (“Aptevo”).
